Our findings provide support for a role of pathways related to chromatin structure, gene regulation, and synaptic plasticity in headache chronification and highlight HDAC4 and MARK3 as viable therapeutic targets, particularly considering convergence of their pathways and previous studies showing efficacy of general HDAC inhibitors in the treatment of migraine and MOH symptoms. This evidence concerns the gene MARK3 and migraine disorder.